About HIS Eyeness
HIS Eyeness is a company based in Bengaluru (India) founded in 2017. HIS Eyeness has raised $980.13 thousand across 5 funding rounds from investors including Bisi Reddy, Nandini S Nelivigi and Krimali Manthan Thacker. The company has 90 employees as of April 02, 2024. HIS Eyeness offers products and services including Moxifloxacin Eye Drops, Nepafenac Eye Drops, Carboxymethyl Cellulose Eye Drops, Sodium Hyaluronate Eye Drops, and Cyclosporine Eye Drops. HIS Eyeness operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
- Headquarter Bengaluru, India
- Employees 90 as on 02 Apr, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name His Eyeness Ophthalmics Private Limited
- Date of Incorporation 08 Aug, 2017
- Jurisdiction Bangaluru, Karnataka, India
-
Annual Revenue
$3.53 M (USD)71.96as on Mar 31, 2023
-
Net Profit
$127.15 K (USD)42.81as on Mar 31, 2023
-
EBITDA
$185.97 K (USD)-9.71as on Mar 31, 2023
-
Total Equity Funding
$980.13 K (USD)
in 5 rounds
-
Latest Funding Round
$33.04 K (USD), Seed
Apr 01, 2022
-
Investors
& 15 more
-
Employee Count
90
as on Apr 02, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HIS Eyeness
HIS Eyeness offers a comprehensive portfolio of products and services, including Moxifloxacin Eye Drops, Nepafenac Eye Drops, Carboxymethyl Cellulose Eye Drops, Sodium Hyaluronate Eye Drops, and Cyclosporine Eye Drops.
Eye drops to treat bacterial eye infections effectively.
Eye drops for reducing inflammation in ocular conditions.
Relieves dry eyes caused by environmental factors.
Moisturizes eyes to alleviate dryness and discomfort.
Treats inflammatory dry eye conditions with targeted therapy.
Delivers medication for chronic diseases like glaucoma safely.
Cleans eyelids to manage specific ocular health issues.
Supports overall eye health with scientifically recommended ingredients.
Funding Insights of HIS Eyeness
HIS Eyeness has successfully raised a total of $980.13K across 5 strategic funding rounds. The most recent funding activity was a Seed round of $33.04 thousand completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HIS Eyeness
HIS Eyeness has secured backing from 16 investors, including angel investors. Prominent investors backing the company include Bisi Reddy, Nandini S Nelivigi and Krimali Manthan Thacker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BR
Bisi Reddy |
Angel investor and entrepreneur, known for early-stage tech investments in India.
|
Locked | Locked | Locked |
|
NS
Nandini S Nelivigi |
-
|
Locked | Locked | Locked |
|
KM
Krimali Manthan Thacker |
-
|
Locked | Locked | Locked |
Investor details for HIS Eyeness
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HIS Eyeness
Investment portfolio details for HIS Eyeness
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HIS Eyeness
Detailed financials for HIS Eyeness
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
His Eyeness Comparisons
Peer comparison for HIS Eyeness
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HIS Eyeness
HIS Eyeness operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Viral vector-based gene therapies for retinal diseases are developed.
|
Detailed competitors of HIS Eyeness
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on His Eyeness
Complete news archive for HIS Eyeness
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HIS Eyeness
HIS Eyeness was founded in 2017.
HIS Eyeness is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
HIS Eyeness is a funded company, having raised a total of $980.13K across 5 funding rounds to date.
As of Apr 02, 2024, the latest employee count at HIS Eyeness is 90.
Annual revenue of HIS Eyeness is $3.53M as on Mar 31, 2023.
HIS Eyeness was founded in 2017 in Bengaluru, India, within the eye care sector. A portfolio of products is developed, encompassing topical anti-infective and anti-inflammatory eye drops, dry eye therapies, preservative-free options for chronic conditions such as glaucoma, eyelid hygiene solutions, and ocular nutrients. Operations center on addressing various ocular health needs through these formulations.
HIS Eyeness's top competitors include Annexon, Alimera Sciences and MeiraGTx.
HIS Eyeness offers Moxifloxacin Eye Drops, Nepafenac Eye Drops, Carboxymethyl Cellulose Eye Drops, Sodium Hyaluronate Eye Drops, and 4 more products and services.
HIS Eyeness has 16 investors. Key investors include Bisi Reddy, Nandini S Nelivigi, Krimali Manthan Thacker, Baljit Singh, and Rohan Chauhan.
The valuation of HIS Eyeness is $1.35M as of Apr 2022.